via The Scientist RSS https://ift.tt/B8zYSCc Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today introduced a range of antibodies that are specific to cemiplimab (Libtayo) and inhibit the binding of the drug to its target, human programmed death receptor-1 (PD-1). https://ift.tt/tyxmH5P April 15, 2022 at 12:22AM